Synergy Pharmaceuticals (SGYP) Upgraded by ValuEngine to “Sell”

ValuEngine upgraded shares of Synergy Pharmaceuticals (NASDAQ:SGYP) from a strong sell rating to a sell rating in a research note released on Monday, May 7th.

A number of other research analysts also recently issued reports on the stock. Cantor Fitzgerald reiterated a buy rating and set a $10.00 target price on shares of Synergy Pharmaceuticals in a research report on Thursday, January 25th. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a hold rating to a buy rating and set a $2.25 target price on the stock in a research report on Friday, February 16th. Oppenheimer reiterated a hold rating on shares of Synergy Pharmaceuticals in a research report on Thursday, March 22nd. BidaskClub upgraded shares of Synergy Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, January 23rd. Finally, HC Wainwright set a $7.00 price target on shares of Synergy Pharmaceuticals and gave the company a buy rating in a research note on Monday, January 8th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Synergy Pharmaceuticals currently has an average rating of Hold and a consensus price target of $8.08.

Shares of Synergy Pharmaceuticals stock traded down $0.01 during trading on Monday, reaching $1.65. 12,515 shares of the company traded hands, compared to its average volume of 5,037,810. The company has a quick ratio of 2.71, a current ratio of 3.09 and a debt-to-equity ratio of -3.01. Synergy Pharmaceuticals has a 1-year low of $1.71 and a 1-year high of $1.78. The company has a market capitalization of $431.80 million, a PE ratio of -1.62 and a beta of 1.22.



Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. The company had revenue of $8.59 million for the quarter, compared to the consensus estimate of $11.18 million. During the same quarter in the previous year, the company earned ($0.30) EPS. Synergy Pharmaceuticals’s quarterly revenue was up 776.5% compared to the same quarter last year. sell-side analysts expect that Synergy Pharmaceuticals will post -0.55 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. HBK Sorce Advisory LLC bought a new stake in Synergy Pharmaceuticals during the 4th quarter valued at $103,000. Sandy Spring Bank bought a new stake in Synergy Pharmaceuticals during the 4th quarter valued at $109,000. MetLife Investment Advisors LLC bought a new stake in Synergy Pharmaceuticals during the 4th quarter valued at $124,000. Lehman Financial Resources Inc. increased its stake in Synergy Pharmaceuticals by 405.9% during the 4th quarter. Lehman Financial Resources Inc. now owns 68,300 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 54,800 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its stake in Synergy Pharmaceuticals by 354.8% during the 4th quarter. Teacher Retirement System of Texas now owns 83,552 shares of the biopharmaceutical company’s stock valued at $186,000 after purchasing an additional 65,182 shares in the last quarter. Institutional investors and hedge funds own 51.70% of the company’s stock.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply